tiprankstipranks
Trending News
More News >

Eledon Pharmaceuticals Holds Annual Stockholders Meeting

Story Highlights
Eledon Pharmaceuticals Holds Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Eledon Pharmaceuticals ( (ELDN) ).

On June 10, 2025, Eledon Pharmaceuticals, Inc. held its Annual Meeting of Stockholders, where four key proposals were voted on. The stockholders elected three Class II Directors for a term ending in 2028, approved amendments to increase authorized shares and provide exculpation for certain officers, and ratified Deloitte & Touche LLP as the independent accounting firm for 2025.

The most recent analyst rating on (ELDN) stock is a Buy with a $20.50 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.

Spark’s Take on ELDN Stock

According to Spark, TipRanks’ AI Analyst, ELDN is a Underperform.

Eldon Pharmaceuticals faces significant financial challenges with a lack of revenue and persistent losses, reflected in its low financial performance score. The stock’s technical indicators point towards a bearish trend, further compounded by a negative P/E ratio and no dividend yield. The company’s future hinges on successful product development or strategic financial interventions to improve its financial and market position.

To see Spark’s full report on ELDN stock, click here.

More about Eledon Pharmaceuticals

Average Trading Volume: 214,036

Technical Sentiment Signal: Sell

Current Market Cap: $179M

Find detailed analytics on ELDN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1